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P-glycoprotein (Pgp) is a well-defined ATP-binding cassette (ABC) protein and a close relative of cystic fibrosis transmembrane
conductance regulator (CFTR), whose dysfunction causes cystic fibrosis (CF). It is postulated that Pgp can complement deficient CFTR
functions because of structural and functional homologies. One of the most relevant functions appears to be the regulation of ATP release,
which influences mucociliary clearance in respiratory epithelia by nucleotide receptor stimulation. However, mechanisms involved in ATP
secretion remain a controversial issue. In the present study, CF epithelial cells (~CFTE29o´) were transduced with the retroviral vector MP1m
encoding Pgp, and thus, a stable Pgp-overexpressing CF cell line (~CFTE29o´Pgp) was established and used for studies of hypothesized
CFTR complementation. In addition, overexpression of native Pgp in ~CFTE29o´ could also be achieved by long-term treatment with
colchicine, a drug, which may be of great interest in CF therapy. We confirmed that overexpression of Pgp causes a significant increase in
cellular ATP release, which could even be enhanced by stimulation with hypoosmolar medium. A potential clinical benefit is discussed.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: MDR-1; Colchicine; CFTR; Complementation; Retroviral vector
1. Introduction transport protein also proved to be a regulator of theCystic fibrosis (CF) is the most common autosomal
recessive disease among the Caucasian and Northern
American population with an incidence of approximately
1:2500. The main cause for morbidity and mortality of this
polyexocrinopathy is related to pulmonary manifestations.
This disease is caused by a deficiency in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene [1,2].
CFTR, a member of the ATP-binding cassette (ABC)
protein family, is a glycosylated membrane protein that
serves as a chloride channel [3,4]. In further studies this1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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At first, impairment in these two protein functions was
considered to be the main dysfunction causing CF
symptoms; however, the list of known CFTR functions
seems to grow continuously. Increasingly, only a sub-
ordinate importance is assigned to the role of CFTR as a
Cl channel. Rather an influence on other transmembrane
transport events and cellular functions has to be considered
as more essential. CFTR influences diverse ionic currents
[7] and one of the most important functions seems to be
the regulation of transmembrane ATP transport. It enhan-
ces cellular ATP release [8–10]. Studies of Braunstein et
al. showed that CFTR probably does not transport ATP by
itself but potentiates the activity of separate ATP channels
[11]. In native epithelial cells hypoosmolarity inducing cell
volume increase is a strong stimulus for ATP efflux. This
effect is significantly reduced in CFTR deficient epithelial
cells [12,13]. ATP release is physiologically important
because of its involvement in numerous autocrine and
paracrine control mechanisms [14–16]. Changes of mem-4 (2005) 157 – 168ed by Elsevier B.V. All rights reserved.
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cell volume are regulated by ATP via nucleotide receptor
stimulation. In addition, mucociliary clearance in airway
epithelia is also thought to be controlled by such signaling
pathways [17–19]. Therefore, impaired ATP transport is
proposed to be a relevant factor in CF pathogenesis.
No causal therapy for CF has been developed until now.
New treatment options are in focus of many experimental
and clinical studies. In 1997 Lallemand et al. published a
remarkable casuistry of a 29-year-old CF patient, whose
pulmonary symptoms improved considerably under chemo-
therapy due to a fibrosarcoma [20]. Because of these
observations it has been postulated that drug-induced over-
expression of the multidrug resistance P-glycoprotein (Pgp)
might complement some of the lacking CFTR functions in
respiratory CF epithelial cells. Pgp is a plasma membrane
efflux pump for various substances of diverse chemical
structure [21]. It is the product of the multidrug resistance
protein 1 (MDR1) gene, also a member of the ABC protein
family, and a very close structural relative of CFTR [1]. Both
transport proteins are located in the apical cell membrane
[22]. Common functions of both proteins are the object of
diverse studies. Abraham et al. demonstrated a Pgp-
stimulated increase in cellular ATP efflux [23]; therefore,
Pgp is also suggested to be involved in ATP-dependent
autocrine and paracrine pathways [15,24]. Initial reports
proposed Pgp to transport ATP by itself but it became clearer
that it regulates another ATP channel [25] as was described
for CFTR. These observations support the hypothesis that
some CFTR functions can be replaced by overexpression of
Pgp because of structural and functional similarities. This
might be the basis for a new therapy option for CF. However,
Pgp-associated ATP release mechanisms remain controver-
sial because some studies failed to show a relationship
between Pgp expression and ATP transport [26].
In the present study we investigated whether respiratory
cystic fibrosis epithelial cells (~CFTE29o´) could be
transduced efficiently with a retroviral Pgp-encoding vector.
For the used vector MP1m no application to respiratory CF
cells has been described until now. Furthermore we
achieved stable overexpression of native Pgp in airway CF
cells by treatment with a common drug that might have a
therapeutic benefit in CF. Additionally we investigated the
influence of Pgp overexpression on transmembrane ATP
transport that seems to play a crucial role in regulatory
pathways in respiratory epithelial cells.2. Methods
2.1. ~CFTE29o´ cell line, transduction, and long-term
treatment with colchicine
We used human cystic fibrosis tracheal epithelial cells
[27], which are homozygous for the most frequent CFTR
mutation DF508—a deletion of phenylalanine at position508 of the protein. Cells were grown in Eagle’s MEM plus
10% FCS (BioWhittaker, Verviers, Belgium), plus 1%
penicillin G/streptomycin solution (10,000 U/ml and
10,000 Ag/ml), plus 1% l-glutamine (Biochrome, Berlin,
Germany), and 300 mg of glucose (Merck, Darmstadt,
Germany) per 500 ml of medium. Cells were cultured on
plastic culture flasks coated with a fibronectin solution
consisting of LHC basal medium (Biosource, Verviers,
Belgien), 10% bovine serum albumin (Sigma, Taufkirchen,
Germany), 1% Collagen S Type I (3 mg/ml, Roche,
Mannheim, Germany), and 1% fibronectin from human
plasma (0,1%, Sigma, Taufkirchen, Germany). All cultures
were performed at 37 -C in an atmosphere of 5% CO2
amount and 85% air.
Some cell populations were transduced with the MDR1
encoding replication incompetent retroviral vector MP1m.
This vector was developed by Baum et al. for efficient
MDR1 expression in hematopoietic cells [28]. An applica-
tion to airway CF cells has not been described yet. The
transduction protocol followed the recommendations of
Baum et al. After transduction, exposure to 20 ng/ml
colchicine (Biochrom, Berlin, Germany) for 20 days
followed by exposure to 40 ng/ml for the next 20 days led
to selection of successfully transduced cells.
Native cell populations were incubated for up to 278
days in medium containing colchicine. Colchicine concen-
tration was increased incrementally from 2 to 20 ng/ml. The
length of treatment time and the rise in colchicine
concentration used were dictated by the rate of cell growth.
Cell numbers of all samples for further investigations
either by quantitative RT-PCR or by flowcytometry were
adjusted to approximately the same amount of 3106/ml or
5106/ml, respectively. Cell viability was proven by trypan
blue exclusion at this time point.
2.2. RNA extraction
RNA extraction was performed from native and trans-
duced ~CFTE29o´ cells, and also from different samples of
long-term colchicine incubated cells. A commercially
available kit (RNeasy\ Mini, Qiagen, Hilden, Germany)
was used. We added 1 Al RNase inhibitor (BioWhittaker,
Verviers, Belgium) per single RNA sample. RNA concen-
tration was determined by photometric measuring using the
UV photometer GeneRay\ (Biometra, Go¨ttingen, Ger-
many). Approximately 1000 ng RNA was used for one
RT-PCR reaction.
2.3. Quantification of MDR1 mRNA levels by TaqMan\
RT-PCR
The relative amount of MDR1 mRNA was investigated
using quantitative RT-PCR on basis of real-time TaqMan\
technology (ABI PRISM\ 7700 Sequence Detection Sys-
tem, Applied Biosystems, Weiterstadt, Germany). Primers
and probes were chosen using Primer Express\ software
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product of interest (79 bp) spanned the borders of MDR1
exon 13 and 14. Thus, amplification of contaminating
genomic DNA was impossible. Purified oligonucleotides
including the used fluorogenic probe were synthesized by
Biosource (Verviers, Belgium). MDR1 forward primer: 5V-
GGAAGCCAATGCCTATGACTTTA-3V, MDR1 reverse
primer: 5V-CAACTGGGCCCCTCTCTCTC-3V, MDR1
probe: 5V-(FAM)-TGAAACTGCCTCATAAATTTGA-
CACCCTGG-(TAMRA)-3V. Glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) mRNA served as an active
reference and internal standard of a constitutively high
expressed housekeeping gene. With that, normalization of
measured MDR1 mRNA amounts allowed a comparison
between samples and we could also check whether the cell
treatment had an influence on the transcription level of the
housekeeping gene. GAPDH probe and primers are compo-
nents of the TaqMan\ GAPDH Control Reagents kit
(Applied Biosystems, Weiterstadt, Germany). GAPDH for-
ward primer: 5V-GAAGGTGAAGGTCGGAGTC-3V,
GAPDH reverse primer: 5V-GAAGATGGTGATGG-
GATTC-3V, GAPDH probe: 5V-(JOE)-CAAGCTTCC-
CGTTCTCAGCC-(TAMRA)-3V. Investigation of both
MDR1 and GAPDH mRNA took place simultaneously in
one reaction tube as a so-called multiplex-PCR. One
reaction mixture of 20 Al contained about 1000 ng of total
RNA, 900 nM of each MDR1 primer, 50 nM MDR1 probe,
50 nM of each GAPDH primer, 100 nM of GAPDH probe,
RNase-free water and the following reagents of the
TaqMan\ EZ RT-PCR Core Reagents kit (Applied Bio-
systems, Weiterstadt, Germany): 0.1 U/Al rTth DNA
polymerase, 1 TaqMan\ EZ buffer, 6 mM Mn(Oac)2,
0.1 U/Al AmpErase UNG, and 300 AM of each dNTP.
Mixtures were pipetted into MicroAmp\ Optical 96-well
Reaction plates (Applied Biosystems, Weiterstadt, Ger-
many) to put in the 7700 Sequence Detector. After
activation of AmpErase UNG at 50 -C for 2 min, reverse
transcription at 60 -C for 45 min, and activation of rTth
DNA polymerase and deactivation of AmpErase UNG at 95
-C for 5 min, PCR was run for 40 cycles (parameters: 94 -C
for 20 s, 60 -C for 1 min). The definite evaluation of the
PCR results took place as relative quantification with help
of standard curves. Standard curves for MDR1 mRNA and
GAPDH mRNAwere determined per PCR run by using six
different concentrated samples (1-, 0.5-, 0.2-, 0.1-, 0.05-,
and 0.025-fold) of human control RNA (TaqMan\ GAPDH
Control Reagents, Applied Biosystems, Weiterstadt, Ger-
many) in an amount of 3 Al per single reaction. Other PCR
reagents were the same as described above.
Every single RNA sample was analyzed 3 times and
negative controls were part of all PCR runs. PCR evaluation
followed recommendations of the ABI\ PRISM manual
(Schild, T.A.: Introduction to the Real-time TaqMan\ PCR
technology, Version 2.1). A relative quantification strategy
was used, in which the unknown quantities of MDR1
mRNA of tranduced or colchicine treated cell samples wererelated to native cell samples. Thus the amount of MDR1
mRNA was indicated semi-quantitatively as an n-fold
amount.
2.4. Flowcytometric measurement of Pgp presence and
transportation function
We confirmed Pgp expression by indirect immunfluor-
escence using a specific mouse-anti-human Pgp-antibody
(UIC2 IgG2a, Immunotech, Marseille, France) and a FITC-
labeled polyclonal goat-anti-mouse IgG-antibody (GAM Ig
FITC, Becton Dickinson, San Jose, USA). Per sample of
interest, 100 Al cell suspension (5106 cells/ml) was
incubated with 5 Ag UIC2 IgG2a at 4 -C for 30 min. After
washing with PBS (Biochrom, Berlin, Germany) twice, a
second incubation step was performed with GAM Ig FITC at
4 -C for 15 min in the dark. Afterwards, cells were washed
three times and resuspended in 500 Al PBS. Flowcytometric
measurements were carried out on a FACSCalibur\ (Becton
Dickinson, San Jose, USA) with 515 nm as the emission
maximum according to the FITC-spectrum. We analyzed
25,000 cells per sample. Results were evaluated using
CellQuest\ software (Becton Dickinson, San Jose, USA).
We always confirmed specificity of the Pgp-antibody-
reaction by also analyzing cells incubated with an isotype-
matched control antibody (monoclonal mouse-anti-human
IgG2a of unknown specificity, Dako, Kopenhagen, Den-
mark). For negative controls, the FITC-labeled secondary
antibody only without UIC2 IgG2a was added to cell
suspension.
Pgp transport function was investigated via a rhodamine
123 accumulation and efflux assay. Rhodamine 123, a
fluorogenic substance with an emission maximum of 520
nm, is a known substrate transported by Pgp [21]. First, cell
samples of interest were cultured without any colchicine for
24 h in order to avoid inhibition of rhodamine transport by
colchicine. 200 Al of the washed cell suspension (5106
cells/ml) was then incubated with 0.1 Ag/ml rhodamine 123
(Sigma Aldrich, St. Louis, USA) for 30 min in the dark.
After two washes with PBS, 25,000 cells from the
‘‘accumulation period’’ were analyzed by flowcytometry.
The ‘‘efflux period’’ was assessed after incubation of the
cells in PBS for 1 h. Once again cells were washed and
examined on a FACSCalibur. Negative and autofluores-
cence controls without rhodamine were also analyzed.
The same procedures were carried out after initial mixture
of cell suspensions with 20 AM cyclosporine A (CsA,
Sandimmun\, Novartis, Nu¨rnberg, Germany), which is an
efficient blocker of Pgp transport functions [29,30]. All
other experimental steps were as described above.
2.5. Analysis of ATP efflux via bioluminescence assay
(luciferin-luciferase assay)
Determination of ATP in extracellular media by bio-
luminescence is a well-established and sensitive method
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oxidation emitting light [12,31,32]. ~CFTE29o´ cells of
interest (native and MP1m transduced) were cultured in
every second well of a 96-well microplate (Corning
Incorporated, New York, USA). Approximately 104 con-
fluent grown cells per well were then washed twice with
PBS and then incubated with 50 Al PBS per well for 10 min.
ATP release has reached a steady-state level after this time
as seen in preliminary studies: Under basic conditions ATP
release reached its maximum after 2–3 s and staid on this
maximal level for up to 10 min. Then ATP concentrations
declined probably due to substrate limitation. The same
protocol was followed under hypoosmolar conditions with
the same results (data not shown). Afterwards, each super-
natant was pipetted into the neighboring well for the
measurement of the secreted ATP concentration. The plate
was placed into the luminometer (Anthos Labtec Instru-
ments, Wals, Austria) and 50 Al luciferin-luciferase reagent
(ATP bioluminescence assay kit HSII, Roche Molecular
Biochemicals, Mannheim, Germany) was injected in every
well containing extracellular fluid. We chose this kind of
experimental setting to avoid direct contact of the reagent
with the cells to prevent cell-lytic effects which would
falsify the conclusion about the cellular ATP efflux. After a
lag time of 1 s, photon release generated by the chemical
reaction was quantified as arbitrary light units over 10 s in
complete darkness. For evaluation of measurements we used
the LucySoft software (Version 1.4, Anthos Labtec Instru-
ments, Wals, Austria). ATP concentrations were calculated
with the help of a calibration curve obtained from six
standard solutions (ATP Bioluminescence assay kit HSII,
Roche Molecular Biochemicals, Mannheim, Germany) of
known ATP concentrations (1.65E10 up to 1.65E4
mol/l). ATP efflux was also performed under hypotonicFig. 1. Example of one quantitative RT-PCR run for the analysis of MDR1-mRN
transduced with MP1m (grey) and native ~CFTE29o´ cells (black). Each sample wa
vector coding for Pgp led to an increase of MDR1 gene transcription reflected
difference of the simultaneously measured active reference (GAPDH-mRNA) waconditions by incubating cells with a hypotonic 0.75 PBS
solution for 10 min. Otherwise the protocol was as
described above.
2.6. Statistics
Results are expressed as meansTSD with n representing
the number of repetitions for an experiment. When
appropriate, statistical significance was tested by variance
analysis using Tamhane test, Student’s t-test or Mann–
Whitney U-test. Values of p <0.05 were considered to be
significant.3. Results
3.1. Transduction of ~CFTE29o´ cells with the retroviral
vector MP1m encoding PgP
~CFTE29o´ cells were transduced with MP1m vector,
which contains the MDR-1 gene coding for Pgp. First,
transcription of the MDR1 gene was checked by quantita-
tive TaqMan\ RT-PCR. Transduced cells showed a signifi-
cant increase in MDR1-transcription on 2088.3T596.5-fold
values compared to native cells ( p <0.001, n =6) (Fig. 1).
No difference in simultaneously measured reference mRNA
(GAPDH mRNA) amounts was found. Next we investigated
Pgp expression using indirect immunofluorescence and
flowcytometry using a Pgp-specific antibody. Pgp-specific
fluorescence signals of native ~CFTE29o´ cells did not vary
from nonspecific fluorescence level as presented in Fig. 2A.
However, in the transduced cells a considerably higher Pgp-
specific fluorescence was found compared to background
and signals of native cells (Fig. 2B). This showed thatA levels is presented here in a comparative manner for ~CFTE29o´ cells
s investigated three times. Transduction of ~CFTE29o´ cells with the MP1m
by an earlier rise of the DRn value (normalized fluorescence signal). No
s observed (data not shown).
Fig. 2. Pgp expression in ~CFTE29o´ cells transduced with MP1m vector was verified flowcytometrically using the specific primary Pgp-antibody UIC2 IgG2a
and a FITC-labelled secondary antibody. A comparison between the analysis for native (A) and ~CFTE29o´ cells transduced with MP1m (B) is shown.
Transduced cells express Pgp represented by a higher fluorescence level if cells were stained with the Pgp-antibody and secondary antibody GAM Ig FITC. No
difference in the fluorescence signals between native and transduced cells was seen for the negative controls. Solid line: specific mouse-anti-human Pgp-
antibody (UIC2 IgG2a) and FITC-conjugated goat-anti-mouse IgG-antibody (GAM Ig FITC). Broken line: GAM Ig FITC. Dotted line: isotype-matched
control antibody (mouse-anti-human IgG2a).
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ciently. Pgp transport functions were tested using the well-
established rhodamine 123 accumulation and efflux assay.
Rhodamine accumulation in Pgp-overexpressing (MP1m
transduced) ~CFTE29o´ cells (~CFTE29o´Pgp) was lower
than in native ~CFTE29o´ cells as shown in Fig. 3A. This
suggested that rhodamine was transported by functional Pgp
in transduced cells. Moreover, an efficient rhodamine
efflux in ~CFTE29o´Pgp also seen in Fig. 3A demonstrated
the fact that these cells expressed functional Pgp.
~CFTE29o´Pgp cells showed a strong decrease in rhod-
amine-specific fluorescence during the efflux period to
those levels seen for autofluorescence only. We found high
fluorescence signals and no difference between accumula-
tion and efflux period in native ~CFTE29o´ cells indicating
absence of functional Pgp. To ensure that rhodamine
transport was caused by Pgp we carried out the same
measurements after preincubation of cells with cyclosporine
A (CsA), which is a putative inhibitor of Pgp transport
function. The CsA-mediated blocking of rhodamine trans-
port is presented in Fig. 3B. After CsA treatment no
difference in rhodamine-specific fluorescence signalsbetween native and Pgp-overexpressing cells could be
detected. These data confirm Pgp-based rhodamine 123
transport.
3.2. Long-term treatment of ~CFTE29o´ cells with rising
colchicine concentrations
Another aim of the present study was to induce stable
Pgp expression by treating cells with a common drug, which
can be used in humans. Colchicine was chosen because it is
a well-known inducer of Pgp expression and there are also
other advantageous effects of colchicine, which might be of
interest in CF therapy. In previous experiments we found a
concentration-dependent increase in MDR1 mRNA in
~CFTE29o´ cells by short-term colchicine stimulation (7-
day exposure). However, membrane Pgp presence could not
be detected by flowcytometry after such a treatment with
relatively high concentrations (4–20 ng/ml) and cells could
not be cultured for a longer time under these conditions
because of cytostatic colchicine effects (unpublished obser-
vations). Thus, we stimulated ~CFTE29o´ cells with
colchicine in increasing concentrations (starting with 2 ng/
Fig. 3. Since rhodamine 123 is transported by Pgp this fluorescent dye can be used to analyze Pgp transport function. ~CFTE29o´ cells transduced with MP1m
expressed functionable Pgp (~CFTE29o´Pgp) proved flowcytometrically via a rhodamine 123 accumulation and efflux assay. ~CFTE29o´Pgp showed a lower
accumulation and a higher efflux of rhodamine 123 in comparison to native cells (A). Addition of the Pgp inhibitor cyclosporine A (CsA) led to a high
rhodamine 123 accumulation and blocked efflux of the dye in ~CFTE29o´Pgp cells reflected by no difference between transduced and native cells (B). Blue
solid line: native ~CFTE29o´ after accumulation period; dashed blue line: ~CFTE29o´ after efflux period; red solid line: ~CFTE29o´Pgp after accumulation
period; dashed red line: ~CFTE29o´Pgp after efflux period.
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endogenous Pgp expression with sufficient protein function.
Pgp expression in 14 various samples of different time
points was investigated by quantitative RT-PCR on tran-
scription level and on protein level by flowcytometry using
a Pgp-specific antibody. Fig. 4 shows the relative amount of
MDR1 mRNA as a function of stimulation time upon
increasing concentrations of colchicine. Colchicine concen-
trations were increased after assessing cell proliferation
microscopically. Viability and good cell conditions under
colchicine exposure were observed during long-term cul-
ture, confirmed by trypan blue exclusion, and were also seen
in the flowcytometric analysis. Cells exhibited no consid-
erable change in MDR1 transcription up to day 216 and up
to 15 ng/ml colchicine (sample 9). Surprisingly, MDR1
transcription showed a sharp rise at the next dose level. We
calculated a 105.3T8.7-fold amount of MDR1 mRNA
(n =3) for sample 10 (day 231, up to 17 ng/ml) in com-
parison to unstimulated cells. MDR1 transcription levels
remained stable in the following samples (#11–#14) on an
approximately 100-fold amount compared to native
~CFTE29o´ cells. This transcription induction was signifi-
cant ( p <0.025). We found no difference in transcription of
the reference gene GAPDH. Flowcytometric analysis, usingthe Pgp-specific antibody UIC2 IgG2a, was in accordance
with the RT-PCR results. Fig. 5 shows comparative
measurements for untreated ~CFTE29o´ cells (Fig. 5A)
and cell sample 10 after 231 days of stimulation with
colchicine (Fig. 5B). Pgp overexpression in the colchicine
long-term treated cells was reflected by a strong Pgp-
specific fluorescence. It is of note that the shift in the
fluorescence signal was as clear as seen in the MP1m
transduced cells (Fig. 2) but the mean fluorescence intensity
was lower, representing a significant but less increase in Pgp
presence on the cell surface achievable by colchicine
treatment.
3.3. ATP release in Pgp-overexpressing ~CFTE29o´ cells
An influence of Pgp on ATP efflux from cells into the
extracellular space is widely discussed [10,23,25] There-
fore we measured ATP release from ~CFTE29o´PgP cells
by a well-established bioluminescence assay based on
ATP dependence of luciferase mediated luciferin oxida-
tion. Fig. 6 shows extracellular ATP concentrations for
native ~CFTE29o´ and ~CFTE29o´Pgp cells in a com-
parative manner. First, ATP release under isotonic con-
ditions was measured (Fig. 6A). We found a significantly
Fig. 4. ~CFTE29o´ cells were long-term exposed to rising concentrations of colchicine (treatment steps are shown as grey background in the diagram). Fourteen
different samples of ~CFTE29o´ cells stimulated with colchicine were investigated by quantitative RT-PCR to analyze MDR1 transcription. Relative levels of
MDR1 mRNA are represented by the solid black curve as a function of treatment time and concentration of colchicine. After 231 days of exposure (up to 17 ng/
ml) a sharp rise in the MDR1 transcription up to an approximately 100-fold amount compared to untreated cells could be observed. *Significant increase of
MDR1 mRNA in samples 10–14 in comparison to the previous samples 1–9 ( p <0.025, n =3).
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expressing cells compared to the value for native cells:
7.577E9T2.424E9 mol/l (n=48) versus 3.207E9T
8.54678E10 mol/l (n=48) with p <0.001. Afterwards
similar experiments were performed in hypoosmolar me-
dium (PBS, 75% concentrated). The difference in ATP efflux
rates between native and Pgp-expressing cells remained
significant ( p <0.001) and further increased as presented in
Fig. 6B. For native cells an extracellular ATP concentration
of 1.277E7T5.09005E8 mol/l (n =36) was observed.
In comparison we found 8.989E7T3.72317E7 mol/l
(n =72) in ~CFTE29o´Pgp. These data indicate a Pgp-
associated ATP efflux, which could be affected positively
by hypoosmolar medium. In addition, we saw that hypo-
osmolality alone also enhanced ATP efflux in both native
and PgP-overexpressing cells.4. Discussion
In the present study overexpression of the CFTR relative
Pgp in a respiratory CF epithelial cell line (~CFTE29o´) was
achieved in two different ways: (a) transduction with a
retroviral vector and (b) induction of native Pgp expression
by incubation of cells with increasing colchicine concen-
trations. A Pgp-associated cellular ATP release could be
comprehended by using a luciferin-luciferase assay.
Pgp, the product of the MDR1 gene, is a well-defined
member of the ABC protein family that operates as a pump
for numerous chemically diverse substrates serving as aprotective mechanism for cells. However, many other Pgp
functions are discussed which might play important
physiological roles in tissues [33]. Primarily, Pgp-mediated
ATP release and associated regulation pathways are in focus
of various studies [23,24,34]. Pgp is a close relative of
CFTR, which is dysfunctional in CF. Both transport proteins
seem to share homologies in structure and function,
including an assumed influence on cellular ATP efflux
[10] and their ability to cause a multidrug resistance
phenotype in cells [35]. Therefore it has been speculated
that some CFTR functions can be partially replaced by those
of Pgp [36]. It is interesting to note that CFTR and Pgp have
complementary expression patterns in some tissues [37–39]
and expression of both genes can be regulated pharmaceuti-
cally by ouabain in opposing senses [40]. Thus, it was
concluded that both proteins might have some analogous
functions. Coordination of complementary CFTR and Pgp
expression and activity could be regulated by ATP release
induced by the proteins. This can be speculated according to
investigations of Marcet et al., showing that CFTR activity
is reduced by ATP upon nucleotide receptor stimulation
[41]. All these observations support the idea of comple-
mentation of CFTR by Pgp in CF epithelia. Therefore,
induction of Pgp expression and Pgp function in respiratory
CF epithelia might be of clinical relevance.
We established a stable Pgp-expressing CF cell line by
transduction with the retroviral Pgp-encoding vector MP1m,
which was developed by Baum et al. [28]. Their initial aim
of the studies with the MP1m construct was to achieve a
long-term stable Pgp expression in hematopoietic cells to
Fig. 5. Pgp expression in ~CFTE29o´ cells treated with increasing concentrations of colchicine was investigated flowcytometrically by indirect
immunfluorescence using the specific Pgp-antibody UIC2 IgG2a and a secondary antibody labelled with FITC. A comparison between an analysis for
native ~CFTE29o´ cells (A) and ~CFTE29o´ cells after treatment with rising colchicine concentrations for 231 days up to 17 ng/ml (B) is presented. Treated
cells express Pgp shown by a higher fluorescence level if cells were stained with both the primary and secondary antibodies. Solid line: specific mouse-anti-
human Pgp-antibody (UIC2 IgG2a) and FITC-conjugated goat-anti-mouse IgG-antibody (GAM Ig FITC); blocked line: only GAM Ig FITC; dotted line:
isotype-matched control antibody (mouse-anti-human IgG2a).
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presented here it could be shown for the first time that it
is also possible to transduce CF respiratory epithelial cells
with MP1m. Successful transduction was proven on a
transcription level by quantitative RT-PCR and on a protein
level via flowcytometry. We reproducibly found a high
increase in Pgp expression after transduction using both
methods. The established Pgp-overexpressing and CFTR
missing respiratory cell line can now be used for further
investigations of Pgp functions and postulated complemen-
tation of CFTR functions.
Furthermore we demonstrated that a durable Pgp over-
expression in ~CFTE29o´ cells could also be achieved by
long-term incubation with rising colchicine concentrations.
We observed an increase of MDR1 transcription to
approximately 100-fold amounts compared to native cells
after a 231-day treatment with colchicine concentrations up
to 17 ng/ml. Pgp expression is mainly regulated on the
transcription level. In fact, a clear increase in Pgp presence
in treated cells was documented flowcytometrically using a
Pgp-specific antibody. Colchicine is a well-known substratetransported by Pgp. Some investigators reported that Pgp
expression levels correlate directly with relative colchicine
resistance of cells [21,42] and it is generally accepted that
colchicine can serve as an inducer of Pgp expression
[36,37]. Since this induction effect is not Pgp-specific we
cannot exclude that other resistance proteins were up-
regulated in consequence of colchicine exposure. But we
definitely could rule out an induction of the transcription of
multidrug resistance-associated protein 1 (MRP 1) by
quantitative RT-PCR measurements (data not shown). In
the present study, the colchicine concentration, which led to
a Pgp induction, exceeds the in vivo serum concentration of
usual therapy regimes (approximately 4 ng/ml) but tissue
concentrations might be considerably higher due to accu-
mulation in tissues [43]. Accordingly, colchicine accumu-
lation in the lung has been described [44]. A possible use of
colchicine in CF therapy has been suggested by Altschuler
in a way that treatment with colchicine might induce Pgp
expression resulting in a replacement of impaired CFTR
functions [36]. In addition the drug could also have some
other useful therapeutic effects [45]. Anti-inflammatory and
Fig. 6. ATP release in native ~CFTE29o´ and cells overexpressing Pgp (~CFTE29o´Pgp) was measured by bioluminescence assay (luciferin-luciferase assay)
under isotonic (A) and hypotonic (B) conditions. A comparison between the results for native (left) and ~CFTE29o´Pgp cells (right) is presented. A higher
extracellular ATP concentration was found in the Pgp-expressing cells under isotonic as well as under hypotonic conditions. *Significant increase of
extracellular ATP concentration ( p <0.001, n =36–72).
N. Naumann et al. / Journal of Cystic Fibrosis 4 (2005) 157–168 165also antifibrotic properties have been reported [46]. Sermet-
Gaudelus et al. carried out a preliminary clinical study
determining colchicine effects in 8 CF patients [47]. They
could demonstrate some therapeutic success and respiratory
function improved significantly in five out of these eight
colchicine treated CF patients.
We also provide here further evidence for a Pgp-
associated cellular ATP release. A considerably increased
ATP concentration in extracellular space in isoosmolar
medium was measured for ~CFTE29o´Pgp in comparison
to unmodified cells using a highly sensitive biolumines-
cence assay. Our findings show that Pgp function partic-
ipates in transmembrane ATP transport and thus are in
agreement with various previous studies. One of the first
demonstrations that Pgp overexpression enhances ATP
efflux was shown in Chinese hamster ovary cells by
Abraham and coworkers [23]. However, ATP transport doesnot appear to be carried out by the protein itself but by
regulating a separate ATP channel [25]. Regulation of ATP
excretion might be the most relevant functional similarity
between both ABC transporters Pgp and CFTR. A role of
CFTR in ATP release is frequently described in the literature
[48–50]. Taylor et al. found an impairment of apical ATP
release in different CFTR deficient cell lines including
~CFTE29o´ [11]. Still, CFTR-associated ATP secretion is
controversial [51–54] and Pgp-mediated or regulated ATP
transport has also been questioned [26]. Nonetheless, our
data confirm that there is an association between Pgp
expression and ATP secretion into the extracellular space.
Native ~CFTE29o´ cells also release some ATP, even
without detectable CFTR and Pgp expression, indicating
involvement of additional mechanisms in ATP fluxes. Rise
of ATP concentration in extracellular fluid might be
explained by cell damage due to experimental procedures.
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result of exocytosis events during membrane recycling
[55,56] or is influenced by a special K+ channel activation,
if mechanical cell stress occurs, as proposed by Ito et al.
[54]. It is widely accepted that ATP release is induced by
mechanical stimuli, such as hypotonic cell swelling, mem-
brane stretch, and shear stress [12,13,55,56]. Cell shrinkage
in hyperosmolar medium was recently also described as a
trigger of ATP transport [57]. Other investigations have
shown that changes in intracellular Cl rather than changes
in cell volume may influence nucleotide-mediated signaling
pathways [58]. Our present findings are consistent with
previously described hypotony-induced ATP release. In
extracellular fluid of both native and ~CFTE29o´Pgp cells,
we detected increased ATP concentrations under hypoos-
molar conditions in comparison to results under isotonic
conditions. In addition we also found a greater difference of
ATP concentration between both cell groups than seen
before in isotony. We interpret these results as follows:
Hypotony resulting in cell swelling can increase Pgp-
mediated ATP release in respiratory epithelial cells. This
suggestion was already made by Schwiebert, who explained
regulatory volume decrease (RVD) after cell swelling upon
Pgp-associated ATP efflux and a following increased Cl
and fluid secretion and inhibited Na+ absorption via
autocrine regulation [15]. Previous publications reported
Pgp-modulated RVD [59,60] and confirmed an improved
cellular recovery and survivability in Pgp-overexpressing
cells in hypoosmolality [24]. It cannot be completely ruled
out that the observed effects are the result of Pgp-
independent mechanisms, which might be stimulated by
hypotony as discussed above. A combination of Pgp-
associated and -non-associated pathways influencing ATP
release may be the most probable explanation.
ATP operates as an autocrine and paracrine signal-
molecule upon different nucleotide membrane receptors
like P2Y and P2X. Thus ATP is involved in numerous
cellular processes such as stimulation of Cl currents,
inhibition of Na+ absorption [61,62], and cell volume
regulation [63]. Furthermore, nucleotide-mediated signaling
regulates ciliary beat frequency and mucociliary clearance in
airway epithelia. This is probably regulated by a P2X
receptor-mediated induction of cellular Ca2+ influx [19].
Assuming CFTR-associated ATP transport is important, it
can be suspected that dysfunction of ATP efflux and of
associated autocrine and paracrine regulatory mechanisms
play a crucial role in the pathogenesis of CF lung
manifestation. Therefore, nucleotide P2 receptor agonists
might be useful in CF therapy [64]. Alternatively, hypothe-
sized complementation of CFTR functions by overexpres-
sion of Pgp, for example drug-induced, may provide a
therapeutic option. It is remarkable that a 100-fold induction
in MDR1 transcription and therefore a significant increase
of Pgp expression is achievable by colchicine—a drug more
suitable for long-term application than most of the other
known Pgp-inducers. Although not at such high levels asseen in MP1m transduced cells, we suggest that the
observed colchicine-induced Pgp overexpression may have
a beneficial impact on cellular ATP release in CF airway
epithelia and therefore on mucociliary clearance possibly
explaining the clinical observation described by Lallemand
et al. and Sermet-Gaudelus and colleagues [20,47].
In conclusion we established a stable Pgp-expressing
respiratory CF cell line by transduction with the retroviral
vector MP1m and also by long-term cell treatment with
colchicine. We provide further evidence for Pgp-associ-
ated ATP release, which is increased under hypotonic
conditions.
Further investigations are required to provide additional
insight into Pgp functions and coupled regulatory pathways,
primarily ATP release-associated mechanisms such as
mucociliary clearance. It is of extraordinary clinical
relevance to answer the question whether Pgp can func-
tionally complement CFTR. This might offer new thera-
peutic options for CF.Acknowledgements
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